Drug Trial Radar · NCT04736706
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,688
Actual
Start
Apr 14, 2021
Primary completion
Feb 4, 2026
Study completion Apr 22, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Eisai Inc.
- First posted
- Feb 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
Conditions
- Carcinoma, Renal Cell
Interventions
PembrolizumabBiological
Pembrolizumab 400 mg administered Q6W via IV infusion
BelzutifanDrug
Belzutifan 120 mg administered QD via oral tablet
Pembrolizumab/QuavonlimabBiological
Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
LenvatinibDrug
Lenvatinib 20 mg administered QD via oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 57 months
- Overall Survival (OS)Time frame: Up to approximately 57 months
Locations
262 sites in 35 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham ( Site 0010)
Birmingham, Alabama
UC San Diego ( Site 0050)
La Jolla, California
Cedars Sinai Medical Center ( Site 0027)
Los Angeles, California
University of California Irvine ( Site 0029)
Orange, California
UCLA Hematology Oncology Santa Monica ( Site 0048)
Santa Monica, California
Hartford Hospital ( Site 0024)
Hartford, Connecticut
Advent Health Hematology & Oncology ( Site 0003)
Orlando, Florida
University Cancer & Blood Center, LLC ( Site 0057)
Athens, Georgia
Emory University Winship Cancer Institute ( Site 0012)
Atlanta, Georgia
Rush University Medical Center ( Site 0040)
Chicago, Illinois
Parkview Cancer Institute ( Site 0088)
Fort Wayne, Indiana
Norton Cancer Institute - St. Matthews ( Site 0065)
Louisville, Kentucky
Ochsner Medical Center ( Site 0049)
New Orleans, Louisiana
New England Cancer Specialists ( Site 0082)
Scarborough, Maine
Massachusetts General Hospital ( Site 0094)
Boston, Massachusetts
Beth Israel Deaconess Medical Center ( Site 0089)
Boston, Massachusetts
Dana Farber Cancer Institute ( Site 0093)
Boston, Massachusetts
Lahey Hospital & Medical Center ( Site 0090)
Burlington, Massachusetts
Henry Ford Hospital ( Site 0038)
Detroit, Michigan
Cancer & Hematology Centers of Western Michigan ( Site 0018)
Grand Rapids, Michigan
HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
Saint Louis Park, Minnesota
Regions Hospital ( Site 0095)
Saint Paul, Minnesota
University of Mississippi Medical Center ( Site 0037)
Jackson, Mississippi
Dartmouth Hitchcock Medical Center ( Site 0075)
Lebanon, New Hampshire
Roswell Park Cancer Institute ( Site 0032)
Buffalo, New York
R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)
Lake Success, New York
Sidney Kimmel Center for Prostate and Urologic Cancers ( Site 0055)
New York, New York
Oregon Health & Science University ( Site 0071)
Portland, Oregon
Ralph H. Johnson VA Center ( Site 0073)
Charleston, South Carolina
University of Tennessee Medical Center Knoxville ( Site 0019)
Knoxville, Tennessee
Vanderbilt University Medical Center ( Site 0069)
Nashville, Tennessee
UTSW Medical Center ( Site 0015)
Dallas, Texas
Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)
Wenatchee, Washington
Liverpool Hospital ( Site 4006)
Liverpool, New South Wales, Australia
Macquarie University ( Site 4007)
Macquarie University, New South Wales, Australia
Lyell McEwin Hospital ( Site 4004)
Elizabeth Vale, South Australia, Australia
Monash Health ( Site 4008)
Clayton, Victoria, Australia
Fiona Stanley Hospital ( Site 4009)
Murdock, Western Australia, Australia
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0302)
São Paulo, Brazil
BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0300)
São Paulo, Brazil
Showing 40 of 262 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.